A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication
Clinical trial NCT05628103 · COMPLETED
Trial details
- NCT number
- NCT05628103
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-12-19
- Primary completion
- 2024-04-01
- Enrollment
- 101
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.